An Evaluation of Maternal Position During Cesarean Delivery (Tilt)

November 10, 2026 updated by: Adam Sachs, Hartford Hospital

A Randomized Controlled Trial Evaluating Maternal Tilt During Cesarean Section

During Cesarean Delivery pregnant women are frequently tilted to the left 15 degrees to reduce compression of the major blood vessels by the uterus. Despite this common practice, there is no conclusive evidence to support this practice. In fact it may even be deleterious to have women positioned in this position. The aim of the study is to determine whether or not tilting women to the left during cesarean section (CS) is helpful or detrimental. The authors hypothesize that left uterine displacement of 15 degrees, which is commonly employed, is useless for preventing compression of these blood vessels. To investigate this question, women will be randomly assigned to either be tilted 15 degrees to the left during CS or positioned flat on the table. Fetal acid base status, vasopressor/phenylephrine use, patient satisfaction, maternal complications, and fetal complications will all be collected and compared.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • Hartford, Connecticut, United States, 06102
        • Hartford Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • term pregnant women with an uncomplicated pregnancy course undergoing scheduled cesarean delivery

    • ≥18 years old
    • American Society of Anesthesiologists (ASA) Physical Status Classification System, class 1 and 2 (i.e., patient is completely healthy (1) or has mild systemic disease (2)
    • Able and willing to consent to participate

Exclusion Criteria:

  • Males

    • <18 years old
    • maternal cardiac/pulmonary/hematologic disorders/renal failure
    • drug/alcohol/tobacco use during pregnancy
    • essential or pregnancy-induced hypertension
    • diabetes greater than 10 years
    • pre-eclampsia or abruptio placenta
    • <37 weeks gestation
    • hemoglobin < 7 g/dL
    • intrauterine growth retardation
    • fetal distress or fetal anomaly
    • Transverse lie
    • Ruptured membranes
    • Severe polyhydramnios or oligohydramnios
    • Multiple gestation
    • severe scoliosis or kyphosis,
    • uterine abnormalities (e.g., large fibroids, bicornuate uterus)
    • Failed spinal (sensory level < T6 after 15 minutes)
    • need to convert to general anesthesia before delivery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supine Position

Pregnant women undergoing C/S in supine position

Placed in a supine position with no 15 degrees left tilt

Experimental: Uterine Displacement Position

Pregnant women undergoing C/S with 15 degrees tilt for uterine displacement

Placed in 15 degrees left uterine displacement (tilt)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
neonatal base deficit from uterine artery immediately after cesarean delivery of the fetus
Time Frame: One data point will be used. The neonatal gas from the uterine artery immediately after delivery
One data point will be used. The neonatal gas from the uterine artery immediately after delivery

Secondary Outcome Measures

Outcome Measure
Time Frame
total phenylephrine use in micrograms prior to delivery
Time Frame: The aggregate of the phenylephrine used immediately after spinal (total of 20 minutes) or until delivery of the baby
The aggregate of the phenylephrine used immediately after spinal (total of 20 minutes) or until delivery of the baby
APGAR scores of the newborn as assessed by the neonatologist immediately after cesarean delivery
Time Frame: 1 and 5 minute apgar scores of the newborn fetus will be compared
1 and 5 minute apgar scores of the newborn fetus will be compared

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Adam Sachs, MD, Hartford Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2016

Primary Completion (Actual)

September 12, 2023

Study Completion (Actual)

September 19, 2023

Study Registration Dates

First Submitted

January 25, 2016

First Submitted That Met QC Criteria

August 15, 2016

First Posted (Estimated)

August 19, 2016

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HHC-2015-0284

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.